ActiveGraf

ActiveGraf is a medical technology company that has emerged as a significant player in the vascular and oncology treatment sectors.

Reviewed by 7wData
Share Email

On this page

Profile

ActiveGraf develops minimally invasive medical technologies for vascular and cancer treatments.

ActiveGraf is a medical technology company that has emerged as a significant player in the vascular and oncology treatment sectors. Founded to address critical gaps in minimally invasive therapies, the company has developed a portfolio of platform technologies aimed at restoring healthy blood flow and expanding cancer treatment options. ActiveGraf's products include the Auryon peripheral atherectomy platform, thrombus management systems like AngioVac and AlphaVac, and the NanoKnife irreversible electroporation platform.

These technologies have driven consistent revenue growth, with the Med Tech segment reporting a 26.1% year-over-year increase in net sales to $35.3 million in Q1 FY2026. The company's financial trajectory is positive, with adjusted EBITDA reaching $2.2 million and a cash position of $38.8 million. ActiveGraf's focus on clinical investments and operational discipline has positioned it for sustained growth, particularly in large, fast-growing global markets. Recent milestones include patient enrollments in the AMBITION BTK and RECOVER-AV trials, as well as the publication of the NanoKnife PRESERVE study in European Urology.

Track ActiveGraf and 240+ vendors.

48k+ subscribers read the daily AI & data note. One email, both newsletters. Unsubscribe anytime.

Who buys this

  • Hospitals and healthcare systems
  • Interventional radiologists
  • Oncology treatment centers
  • Cardiovascular specialists
  • Medical device distributors

Strengths and what to watch

Strengths

  • Strong revenue growth in Med Tech segment (26.1% YoY in Q1 FY2026)
  • Diverse product portfolio addressing large, fast-growing markets
  • Clinical validation with published studies and ongoing trials

Watch for

  • Dependence on a few key products like Auryon and NanoKnife for growth
  • Competitive pressures in the medical technology sector
  • Regulatory risks associated with clinical trials and product approvals

Recent moves

Key Information

Founded
2013
Headquarters
Charlotte, North Carolina, United

Frequently Asked Questions

What does ActiveGraf do?

ActiveGraf develops minimally invasive medical technologies for vascular and cancer treatments. Their product portfolio includes the Auryon peripheral atherectomy platform, thrombus management systems like AngioVac and AlphaVac, and the NanoKnife irreversible electroporation platform, aimed at restoring healthy blood flow and expanding cancer treatment options.

What are ActiveGraf's main products?

ActiveGraf's main products include the Auryon peripheral atherectomy platform for vascular treatments, thrombus management systems like AngioVac and AlphaVac, and the NanoKnife irreversible electroporation platform for cancer therapy. These technologies address critical gaps in minimally invasive therapies and have driven consistent revenue growth.

How is ActiveGraf performing financially?

ActiveGraf reported a 26.1% year-over-year increase in net sales to $35.3 million in Q1 FY2026. The company's Med Tech segment shows strong growth, with adjusted EBITDA reaching $2.2 million and a cash position of $38.8 million, indicating a positive financial trajectory.

What clinical trials is ActiveGraf involved in?

ActiveGraf is currently involved in clinical trials such as AMBITION BTK and RECOVER-AV. These trials aim to validate the efficacy of their minimally invasive technologies, with recent milestones including patient enrollments and the publication of the NanoKnife PRESERVE study in European Urology.

Who are ActiveGraf's primary customers?

ActiveGraf's primary customers include hospitals, healthcare systems, interventional radiologists, oncology treatment centers, cardiovascular specialists, and medical device distributors. Their technologies cater to large, fast-growing markets, addressing critical needs in vascular and cancer treatments.

What are the risks associated with ActiveGraf?

ActiveGraf faces risks such as dependence on key products like Auryon and NanoKnife for growth, competitive pressures in the medical technology sector, and regulatory challenges related to clinical trials and product approvals. These factors could impact their sustained growth and market position.

Sources

  1. investors.angiodynamics.com — Q1 FY2026 financial results and product performance
  2. onecodesoft.com — General market context for case studies
  3. techcrunch.com — Industry trends and layoffs context
  4. investors.datadoghq.com — Comparative financial performance context